Clinical, pathological analysis of 33 cases of embryonal rhabdomyosarcoma of head, neck

doi:10.19438/j.cjoms.2022.03.016

Abstract

Abstract: PURPOSE: To summarize the clinical manifestations, imaging characteristics, treatment and pathological types of embryonal rhabdomyosarcoma (ERMS) in the head and neck, in order to provide reference for the diagnosis and treatment of the disease. METHODS: Thirty-three cases with ERMS diagnosed by pathology in the First Affiliated Hospital of Zhengzhou University from February 2012 to September 2021 were analyzed retrospectively, and their clinicopathological data were analyzed. SPSS 19.0 software package was used for statistical analysis. RESULTS: The age of the patients ranged from 9 months to 59 years old, with an average age of(12.1±13.9) years. The main symptoms were swelling, pain and numbness. It showed low density on CT, medium signal on MRI on T1WI and medium to high signal on T2WI. Immunohistochemical results showed that 22 cases were Desmin positive, 23 were myogenin positive, 22 were MyoD1 positive, and Ki-67 proliferation index was 57%±19%. The Ki-67 index in cases with cervical lymph node metastasis was significantly higher than that in cases without cervical lymph node metastasis [(63.5±10.96)%:(53.4±21.5)%, P=0.022]. ROC curve was used to analyze the power of Ki-67 index in predicting cervical lymph node spread. The area under ROC curve of end-stage patients was 0.75 (P=0.024). A cut-off value of >55% resulted in sensitivity of 100% and specificity of 65%. CONCLUSIONS: Head and neck ERMS is common in children and adolescents. CT, MRI combined with PET-CT and other imaging examinations can guide the diagnosis, treatment and monitoring of recurrence and metastasis. Pathological examination is the gold standard for ERMS diagnosis. Cervical lymph node metastasis is associated with Ki-67 values.

Key words: Embryonal rhabdomyosarcoma, Head and neck, Clinical features, Pathological features

CLC Number:

R739.8

XU Wei-jing, GAO Zhen-jie, FU Kun, GAO Ning, CHENG Long, HE Wei. Clinical, pathological analysis of 33 cases of embryonal rhabdomyosarcoma of head, neck[J]. China Journal of Oral and Maxillofacial Surgery, 2022, 20(3): 292-297.

References

[1] Bisogno G, De Salvo GL, Bergeron C, et al.Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2019, 20(11): 1566-1575.
[2] Sbaraglia M, Bellan E, Dei Tos AP.The 2020 WHO classification of soft tissue tumours: news and perspectives[J]. Pathologica, 2021, 113(2): 70-84.
[3] Drabbe C, Benson C, Younger E, et al.Embryonal and alveolar rhabdomyosarcoma in adults: real-life data from a tertiary sarcoma centre[J]. Clin Oncol (R Coll Radiol), 2020, 32(1): e27-e35.
[4] Radzikowska J, Kukwa W, Kukwa A, et al.Rhabdomyosarcoma of the head and neck in children[J]. Contemp Oncol (Pozn), 2015, 19(2): 98-107.
[5] Iatrou I, Theologie-Lygidakis N, Schoinohoriti O, et al.Rhabdomyosarcoma of the maxillofacial region in children and adolescents: report of 9 cases and literature review[J]. J Craniomaxillofac Surg, 2017, 45(6): 831-838.
[6] Gennaro N, Marrari A, Renne SL, et al.Multimodality imaging of adult rhabdomyosarcoma: the added value of hybrid imaging[J]. Br J Radiol, 2020, 93(1112): 20200250.
[7] McInturff M, Adamson A, Donaldson C, et al. Embryonal rhabdomyosarcoma of the oral cavity[J]. Head Neck Pathol, 2017, 11(3): 385-388.
[8] Jawad N, McHugh K. The clinical and radiologic features of paediatric rhabdomyosarcoma[J]. Pediatr Radiol, 2019, 49(11): 1516-1523.
[9] Inarejos Clemente EJ, Navallas M, Barber Martínez de la Torre I, et al. MRI of rhabdomyosarcoma and other soft-tissue sarcomas in children[J]. Radiographics, 2020, 40(3): 791-814.
[10] Donner D, Feraco P, Meneghello L, et al.Usefulness of 18f-FDG PET-CT in staging, restaging, and response assessment in pediatric rhabdomyosarcoma[J]. Diagnostics (Basel), 2020, 10(12): 1112-1117.
[11] Rosenthal J, Cardona K, Sayyid SK, et al.Nodal metastases of soft tissue sarcomas: risk factors, imaging findings, and implications[J]. Skeletal Radiol, 2020, 49(2): 221-229.
[12] El-Kholy E, El Nadi E, Hafez H, et al.Added predictive value of 18F-FDG PET/CT for pediatric rhabdomyosarcoma[J]. Nucl Med Commun, 2019, 40(9): 898-904.
[13] Jeyaraju M, Macatangay RA, Munchel AT, et al.Embryonal rhabdomyosarcoma with posttherapy cytodifferentiation and aggressive clinical course[J]. Case Rep Pathol, 2021, 2021: 1800854.
[14] Wang X, Feng J, Li Z, et al.Characteristics and prognosis of embryonal rhabdomyosarcoma in children and adolescents: an analysis of 464 cases from the SEER database[J]. Pediatr Investig, 2020, 4(4): 242-249.
[15] Pontes FS, de Oliveira JI, de Souza LL, et al. Clinicopathological analysis of head and neck rhabdomyosarcoma: a series of 10 cases and literature review[J]. Med Oral Patol Oral Cir Bucal, 2018, 23(2): e188-e197.
[16] Rudzinski ER, Teot LA, Anderson JR, et al.Dense pattern of embryonal rhabdomyosarcoma, a lesion easily confused with alveolar rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group[J]. Am J Clin Pathol, 2013, 140(1): 82-90.
[17] Glosli H, Bisogno G, Kelsey A, et al.Non-parameningeal head and neck rhabdomyosarcoma in children, adolescents, and young adults: experience of the European paediatric soft tissue sarcoma Study Group (EpSSG) - RMS2005 study[J]. Eur J Cancer, 2021,151: 84-93.
[18] Gallego S, Bernabeu D, Garrido-Pontnou M, et al.GEIS-SEHOP clinical practice guidelines for the treatment of rhabdomyosarcoma[J]. Clin Transl Oncol, 2021, 23(12): 2460-2473.
[19] Zhang Y, Zhang WL, Huang DS, et al.Prognostic factors in children with head and neck rhabdomyosarcoma: a 12-year retrospective study[J]. Brain Behav, 2020, 10(8): e01697.
[20] Dombrowski ND, Wolter NE, Robson CD, et al.Role of surgery in rhabdomyosarcoma of the head and neck in children[J]. Laryngoscope, 2021, 131(3): E984-E992.
[21] Wen Y, Huang D, Zhang W, et al.Radiation therapy is an important factor to improve survival in pediatric patients with head and neck rhabdomyosarcoma by enhancing local control: a historical cohort study from a single center[J]. BMC Pediatr, 2020, 20(1): 265-274.
[22] Soffer S, Amitai MM, Shimon O, et al.Rhabdomyosarcoma disease spread evaluation on CT scans: association with primary tumor size and Ki-67 proliferation marker[J]. Clin Imaging, 2019, 56: 41-46.
[23] van Erp AEM, Hillebrandt-Roeffen MHS, van Houdt L, et al. Targeting anaplastic lymphoma kinase (ALK) in rhabdomyosarcoma (RMS) with the second-generation ALK inhibitor ceritinib[J]. Target Oncol, 2017, 12(6): 815-826.
[24] Xu B, Suurmeijer A, Agaram NP, et al.Head and neck rhabdomyosarcoma with TFCP2 fusions and ALK overexpression: a clinicopathological and molecular analysis of 11 cases[J]. Histopathology, 2021,79(3): 347-357.
[25] Camero S, Vitali G, Pontecorvi P, et al.DNMT3A and DNMT3B targeting as an effective radiosensitizing strategy in embryonal rhabdomyosarcoma[J]. Cells, 2021,10(11): 2956-2963.
[26] Sun J, Lin W, Li C, et al.Repurposing of posaconazole as a hedgehog/SMO signaling inhibitor for embryonal rhabdomyosarcoma therapy[J]. Am J Cancer Res, 2021,11(9): 4528-4540.